Skip to content

Safety and efficacy evaluation of Esketamine combined with Remazolam in elderly patients undergoing fibrobronchoscopy

Safety and efficacy evaluation of Esketamine combined with Remazolam in elderly patients undergoing fibrobronchoscopy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084672
Enrollment
Unknown
Registered
2024-05-22
Start date
2024-10-21
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless bronchoscope

Interventions

Esketamine Group:Three minutes before the procedure began: Remazolam 0.2mg/kg intravenously
and esketamine 0.3mg/kg and fentanyl 0.5ug/kg 1 minute later
Fentanyl group:Three minutes before the procedure began: Remazolam 0.2mg/kg intravenously, and fentanyl 1.5ug/kg 1 minute later

Sponsors

Deyang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1 Gender is not limited, age 65-85 years old; 2 Patients with ASA grade I-III who received painless fiberoptic bronchoscopy in our hospital; 3 BMI 18-28 kg/m2; 4 No bronchoscopy contraindications; 5 Able to understand the research process and communicate effectively with researchers; 6 Participate voluntarily and sign informed consent.

Exclusion criteria

Exclusion criteria: 1 Severe hypertension or diabetes; 2 Coronary heart disease and severe pulmonary insufficiency; 3 Head trauma or central nervous system or mental illness; 4 difficult airway or hypoxemia; 5 Drug and/or alcohol abuse; 6 Allergic to research drugs; 7 Glaucoma patients or patients with increased intraocular pressure; 8 Blood system diseases; 9 Obvious abnormal liver and kidney function (that is, the indexes are more than one time higher than normal); 10 Patients who do not accept this test.

Design outcomes

Primary

MeasureTime frame
Incidence of respiratory depression;

Secondary

MeasureTime frame
Success rate of fiberoptic operation;recovery time;Incidence of hypertension/hypotension;Time to discharge;Incidence of agitation;QOR-15 rating scale;

Countries

China

Contacts

Public ContactXie An

Deyang People's Hospital

15802821332@163.com+86 158 0282 1332

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026